Patents Examined by Paul J Holland
  • Patent number: 12285029
    Abstract: Alkaline extraction followed by acid precipitation or ultrafiltration method for preparation of protein isolates from oilseeds cakes/meals is followed. The strong alkaline and acidic conditions alter the functional properties of the protein, which adversely affects its quality. The present invention provides a microbial based process to produce protein isolates/concentrates from oilseed cakes/meals or from other similar type of sources either plant or animal origin without addition of strong or diluted acid. The protein is extracted in aqueous media or alkaline aqueous media with or without containing specified salt for specified duration. The extract is centrifuged, mixed with known microbial culture (the process is not limited to the particular strain) and incubated at particular temperature and duration. The precipitated protein is recovered and dried to get protein isolates/concentrates.
    Type: Grant
    Filed: March 27, 2020
    Date of Patent: April 29, 2025
    Assignee: Indian Council of Agricultural Research
    Inventors: Deep Narayan Yadav, Sangita Bansal, Rajesh Kumar Singh, Shyam Narayan Jha
  • Patent number: 12286467
    Abstract: The present invention relates to methods of enhancing transfection in cell culture media supplemented with a plant-produced recombinant mammalian transferrin supplement, as well as kits, and methods of using the supplemented cell culture media to improve growth characteristics of cultured cells for transfection.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: April 29, 2025
    Assignee: INVITRIA, INC.
    Inventors: Steven Clyde Pettit, Mary Ann Michelle Fernandez Santos, Ning Huang
  • Patent number: 12282024
    Abstract: An evaluating method includes an evaluating step of evaluating a state of ketosis in postpartum dairy cows for a dairy cow using at least one value of concentration values of Ala, Arg, Asn, Asp, BCAA, Cit, Cys, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, 3MeHis, Orn, Phe, Pro, Ser, Tau, Thr, Trp, Tyr, and Val and concentration values of ALB, ALT, AST, BHBA, BUN, Ca, gGTP, Glc, NEFA, T-Bil, TCHO, TG, and TP in blood of the dairy cow before parturition.
    Type: Grant
    Filed: February 18, 2021
    Date of Patent: April 22, 2025
    Assignee: Ajinomoto Co., Inc.
    Inventors: Takashi Mikami, Akira Imaizumi, Takayuki Tanaka, Yuki Miyazawa, Mina Nakamura, Kazuki Nakagawa, Takeshi Fujieda
  • Patent number: 12281338
    Abstract: Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids or the modification of nucleic acids or proteins, including editing a single site within the genome of a cell or subject, e.g., within the human genome. In some embodiments, fusion proteins of nucleic acid programmable DNA binding proteins e.g., GeoCas9 or variants thereof, and effector domains, e.g., deaminase domains, are provided. In some embodiments, methods for targeted nucleic acid editing or protein modification are provided. In some embodiments, reagents and kits for the generation of targeted nucleic acid editing proteins, e.g., fusion proteins of a GeoCas9 and effector domains, are provided.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: April 22, 2025
    Assignees: The Broad Institute, Inc., President and Fellows of Harvard College
    Inventors: David R. Liu, Yongjoo Kim
  • Patent number: 12275968
    Abstract: The current invention involves the use of protein lectins produced by plants including the non-toxic carbohydrate binding subunits (B subunits) of plant “AB toxins” (PTB lectins) as delivery vehicles for mobilizing associated drug substances for delivery to animal and human cells. The resulting protein fusions or conjugates retain lectin carbohydrate specificity for binding to cells and cellular trafficking activity so as to deliver an associated drug compound to the site of disease manifestation. One embodiment of this invention concerns the ability of ricin toxin B subunit, as a model PTB lectin, to deliver enzyme replacement therapeutic drugs to cells of several organs of the body including the brain and central nervous system, eyes, ears, lungs, bone, heart, kidney, liver, and spleen for treating lysosomal diseases.
    Type: Grant
    Filed: June 17, 2022
    Date of Patent: April 15, 2025
    Assignee: BIOSTRATEGIES LC
    Inventors: David N. Radin, Carole L. Cramer
  • Patent number: 12270047
    Abstract: The present invention relates to A multicomponent system wherein a first component is an engineered antigen-presenting cell (eAPC) designated component A and a second component is a genetic donor vector, designated component C, for delivery of one or more ORFs encoding an analyte antigen-presenting complex (aAPX) and/or an analyte antigenic molecule (aAM), wherein component A a. Lacks endogenous surface expression of at least one family of aAPX and/or aAM and b. Contains at least two genomic receiver sites, designated component B and component D, each for integration of at least one ORF encoding at least one aAPX and/or aAM, and component C is matched to a component B, and wherein component C is designed to deliver c. A single ORF encoding at least one aAPX and/or aAM or d. Two or more ORF encoding at least one aAPX and/or aAM, wherein the genomic receiver sites B and D are synthetic constructs designed for recombinase mediated exchange (RMCE).
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: April 8, 2025
    Assignee: GENOVIE AB
    Inventors: Reagan Micheal Jarvis, Ryan Edward Hill, Luke Benjamin Pase
  • Patent number: 12258542
    Abstract: The present invention relates to detergent compositions comprising protease variants and alpha-amylases or variants thereof. Furthermore, the present invention relates to methods of using the detergent compositions.
    Type: Grant
    Filed: May 6, 2021
    Date of Patent: March 25, 2025
    Assignee: NOVOZYMES A/S
    Inventors: Carsten Andersen, Yanfei Wang, Wenwen Tao, Bitten Plesner, Elena Genesca Pont
  • Patent number: 12252720
    Abstract: The present invention relates to variants of a parent alpha-amylase. The present invention also relates to polynucleotides encoding the variants and to nucleic acid constructs, vectors, and host cells comprising the polynucleotides, and methods of using the variant enzymes.
    Type: Grant
    Filed: February 6, 2023
    Date of Patent: March 18, 2025
    Assignees: Novozymes A/S, Novozymes North America, Inc.
    Inventors: Carsten Andersen, Randall Deinhammer, Thomas Agersten Poulsen, Miguel Duarte Toscano, Peter Kamp Hansen, Henrik Friis-Madsen, Anders Viksoe-Nielsen, Signe Eskildsen Larsen, Lars L. H. Christensen
  • Patent number: 12252715
    Abstract: The disclosure provides, in various embodiments, fusion proteins comprising a DNA-binding domain, a DNMT3A-binding domain, and a H3K4me0; and polynucleotides and vectors encoding one or more of the fusion proteins. The disclosure also provides, in various embodiments, gene-delivery systems, cells, compositions (e.g., pharmaceutical compositions) and kits comprising one or more of the fusion proteins polynucleotides, or vectors; methods of epigenetically modifying a genomic locus in a cell; and methods of treating a subject (e.g., a human) in need thereof.
    Type: Grant
    Filed: February 16, 2024
    Date of Patent: March 18, 2025
    Assignee: WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Edwin Neumann, Tessa Bertozzi, Jonathan Weissman
  • Patent number: 12246062
    Abstract: Provided are a recombinant acid ?-glucosidase and pharmaceutical composition comprising a recombinant acid ?-glucosidase, wherein the recombinant acid ?-glucosidase is expressed in Chinese hamster ovary (CHO) cells and comprises an increased content of N-glycan units bearing one or two mannose-6-phosphate residues when compared to a content of N-glycan units bearing one or two mannose-6-phosphate residues of alglucosidase alfa. Also provided herein are methods of producing, purifying, and formulating the recombinant acid ?-glucosidase or pharmaceutical composition for administration to a subject and methods of treating a disease or disorder such as Pompe disease using the recombinant acid ?-glucosidase or pharmaceutical composition.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: March 11, 2025
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Hung Do, Russell Gotschall, Richie Khanna, Yi Lun, Hing Char, Sergey Tesler, Wendy Sunderland, Enrique Diloné
  • Patent number: 12247237
    Abstract: The present invention relates to polypeptide variants and methods for obtaining variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Grant
    Filed: April 6, 2020
    Date of Patent: March 11, 2025
    Assignee: Novozymes A/S
    Inventors: Lars Henrik Oestergaard, Annette Helle Johansen, Steffen Danielsen, Roland Alexander Pache, Johanne Moerch Jensen, Frank Winther Rasmussen, Martin Gudmand, Kasper Damgaard Tidemand
  • Patent number: 12234453
    Abstract: Disclosed are methods of altering expression of a gene with a promoter region CTCF binding site. Also disclosed are compositions and methods useful for treating a disease or condition involving over-expression or under-expression of a gene with a promoter region CTCF binding site. Further disclosed are cells and non-human animals with modified a promoter region CTCF binding site, as well as methods for screening for compounds that can modify the expression of a gene with a promoter region CTCF binding site.
    Type: Grant
    Filed: June 5, 2023
    Date of Patent: February 25, 2025
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Jurian Schuijers, Abraham S. Weintraub, John C. Manteiga, Richard A. Young
  • Patent number: 12215361
    Abstract: The disclosure provides, in various embodiments, fusion proteins comprising a DNA-binding domain, a DNMT3A-binding domain, and a H3K4me0; and polynucleotides and vectors encoding one or more of the fusion proteins. The disclosure also provides, in various embodiments, gene-delivery systems, cells, compositions (e.g., pharmaceutical compositions) and kits comprising one or more of the fusion proteins polynucleotides, or vectors; methods of epigenetically modifying a genomic locus in a cell; and methods of treating a subject (e.g., a human) in need thereof.
    Type: Grant
    Filed: February 16, 2024
    Date of Patent: February 4, 2025
    Assignee: WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Edwin Neumann, Tessa Bertozzi, Jonathan Weissman
  • Patent number: 12215373
    Abstract: Methods and compositions (e.g., engineered hosts) are disclosed for use in converting biomass to 3-hydropropionic acid. In particular embodiments, the methods include use of an engineered Rhodosporidium yeast, such as R. toruloides, the engineered R. toruloides having the RT04_8975 gene deleted from its genome, combined with a lignocellulosic hydrolysate, sourced, for example, from a biomass. A promoter for enhancing transport of 3HP is also incorporated by addition to the R. toruloides genome, for example, by modified lithium acetate transformation.
    Type: Grant
    Filed: March 15, 2023
    Date of Patent: February 4, 2025
    Assignee: National Technology & Engineering Solutions of Sandia, LLC
    Inventors: Di Liu, Peter Britton Otoupal, HeeJin Hwang, John Michael Gladden
  • Patent number: 12202876
    Abstract: The present invention relates to a transmembrane domain derived from human LRRC24 protein. More specifically, the present invention relates to a transmembrane domain derived from the human LRRC24 protein (LRRC24P transmembrane domain) or a cell-penetrating peptide, and an intracellular delivery system comprising same. The transmembrane domain derived from the human LRRC24 protein of the present invention can be used to deliver cargo materials such as compounds, biomolecules, and various polymer materials into cells. Since the LRRC24P transmembrane domain of the present invention exhibits higher cell penetration efficiency compared to conventional cell-penetrating peptides and is derived from human proteins, thus avoiding side effects and immune responses caused by peptides derived from foreign proteins, it can be usefully used as an effective intracellular delivery method for compounds, biomolecules, and various polymer materials applied to the human body.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: January 21, 2025
    Assignee: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Seong Jun Kim, Kyun Do Kim, In Su Hwang, Keunbon Ku, Chonsaeng Kim, Bum Tae Kim, Dae Gyun Ahn, Hae Soo Kim, Young Chan Kwon
  • Patent number: 12203116
    Abstract: The present invention relates to methods of providing a biomass residuum and compositions thereof. In particular examples, the biomass residuum includes one or more high value amino acids, even after removal of mixed alcohol components. In particular, the methods include implementing pre-treatment conditions and employing fermentation conditions including modified organisms.
    Type: Grant
    Filed: April 7, 2022
    Date of Patent: January 21, 2025
    Assignee: National Technology & Engineering Solutions of Sandia, LLC
    Inventors: Ryan Wesley Davis, Fang Liu
  • Patent number: 12195749
    Abstract: Disclosed herein are nucleic acid-guided nucleases, guide nucleic acids, and targetable nuclease systems, and methods of use. Disclosed herein are engineered non-naturally occurring nucleic acid-guided nucleases, guide nucleic acids, and targetable nuclease systems, and methods of use. Targetable nuclease systems can be used to edit genetic targets, including recursive genetic engineering and trackable genetic engineering methods.
    Type: Grant
    Filed: March 10, 2022
    Date of Patent: January 14, 2025
    Assignee: Inscripta, Inc.
    Inventors: Andrew Garst, Ryan T. Gill, Tanya Elizabeth Warnecke Lipscomb
  • Patent number: 12194110
    Abstract: Provided herein are novel 10Fn3 domains which specifically bind to PD-L1, as well as imaging agents based on the same for diagnostics.
    Type: Grant
    Filed: September 23, 2021
    Date of Patent: January 14, 2025
    Assignee: Bristol-Myers Squibb Company
    Inventors: Paul E. Morin, David Donnelly, Dasa Lipovsek, Jochem Gokemeijer, Maria N. Jure-Kunkel, David Fabrizio, Martin C. Wright, Douglas Dischino, Samuel J. Bonacorsi, Jr., Ralph Adam Smith, Virginie Lafont, Daniel Cohen
  • Patent number: 12178211
    Abstract: The present invention discloses an endophytic fungal strain Pseudophialophora sp. P-B313 and an application thereof, and belongs to the technical filed of microbial applications. The deposit number of the endophytic fungal strain P-B313 is CCTCC M 2021504, and the scientific name thereof is Pseudophialophora sp. The endophytic fungal strain P-B313 can enhance the resistance of rice against seedling leaf blast with a control efficiency of 87.56% and a disease index reduced by 62.59. The biological control efficiency of the endophytic fungus P-B313 against seedling leaf blast in rice has great value by promotion and applications thereof in the field of agriculture.
    Type: Grant
    Filed: May 14, 2022
    Date of Patent: December 31, 2024
    Assignee: ZHEJIANG ACADEMY OF AGRICULTURAL SCIENCES
    Inventors: Fucheng Lin, Zhenzhu Su, Lin Li, Yan Liang, Kunlun Shen
  • Patent number: 12180502
    Abstract: Disclosed herein are nucleic acid-guided nucleases, guide nucleic acids, and targetable nuclease systems, and methods of use. Disclosed herein are engineered non-naturally occurring nucleic acid-guided nucleases, guide nucleic acids, and targetable nuclease systems, and methods of use. Targetable nuclease systems can be used to edit genetic targets, including recursive genetic engineering and trackable genetic engineering methods.
    Type: Grant
    Filed: May 31, 2022
    Date of Patent: December 31, 2024
    Assignee: Inscripta, Inc.
    Inventors: Andrew Garst, Ryan T. Gill, Tanya Elizabeth Warnecke Lipscomb